Nsanzabaganwa Christian1,*, Byiringiro Fidele1, Hitimana Nadia2, Ndishimye Pacifique3, Daniel Nyamwasa4, Malik Kayumba3, Koutangni Morel Nonhouegnon Gilchrist3,4, Nsanzimana Sabin3, Mutesa Leon3,4
1Rwanda Military Hospital, Kigali, Rwanda
2Clinton Health Access Initiative (CHAI), Kigali, Rwanda
3Rwanda Biomedical Centre, Joint Task Force COVID-19, Rwanda Ministry of Health, Kigali, Rwanda
4Centre for Human Genetics, University of Rwanda, Kigali, Rwanda
Since the virus first emerged in Wuhan, China in December 2019, The COVID-19 pandemic has caused worldwide concern and has become a major public health concern and infected more than 6.5 millions and led to more than 400,000 deaths worldwide [1-4]. Treatments and vaccines have been the focus of the pharmaceutical companies for effectively fighting the pandemic .
Currently, there is no effective treatment for COVID-19 but studies are being conducted to develop a cure and vaccines . Drugs approved or licensed for other indications have been used for treatment of the infected cases .
Nevertheless, global COVID-19 management trends have proven that timely and proper diagnosis as well as early management of symptoms to minimize the number of infected patients migrating from mild/moderate to severe disease translate, in many countries, to effective management of COVID-19 [4,5].